Loading clinical trials...
Loading clinical trials...
A Phase 1 Study to Evaluate Safety, Toxicity, and Potential Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma
Conditions
Interventions
Albuterol Sulfate
Interferon gamma-primed mesenchymal stromal cells (MSCs)
+1 more
Locations
1
United States
Children's Healthcare of Atlanta
Atlanta, Georgia, United States
Start Date
March 16, 2022
Primary Completion Date
December 16, 2022
Completion Date
December 16, 2022
Last Updated
June 3, 2025
NCT06979323
NCT07431021
NCT06664619
NCT07383896
NCT07356310
NCT07282886
Lead Sponsor
Emory University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions